Examining LAG3 Expression in Triple Negative Breast Cancer
The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer
NA · Samsung Medical Center · NCT06259162
This study is testing how a protein called LAG-3 affects treatment outcomes in patients with triple negative breast cancer who are receiving chemotherapy along with an immune therapy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Sex | Female |
| Sponsor | Samsung Medical Center (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06259162 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between LAG-3 expression and immune checkpoint protein expression in patients with triple negative breast cancer undergoing neoadjuvant chemotherapy combined with an immune checkpoint inhibitor. The goal is to understand how these expressions may influence treatment outcomes. By analyzing tissue samples and patient responses, the study aims to provide insights into potential biomarkers for therapy effectiveness.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with triple negative breast cancer who are scheduled to receive neoadjuvant chemotherapy.
Not a fit: Patients with HER2-positive or hormone receptor positive breast cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with triple negative breast cancer.
How similar studies have performed: While this approach is exploring a specific biomarker in a targeted population, similar studies have shown promise in utilizing immune checkpoint inhibitors in cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Planned neoadjuvant chemotherapy * Triple negative breast cancer Exclusion Criteria: * HER2-positive breast cancer * Hormone receptor positive breast cancer
Where this trial is running
Seoul
- Ji-Yeon Kim — Seoul, South Korea (RECRUITING)
Study contacts
- Study coordinator: Ji-Yeon Kim
- Email: jyeon25@skku.edu
- Phone: 82-2-3410-3459
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Triple Negative Breast Cancer, Immune Checkpoint Inhibitor